Printer Friendly

Supply interruptions hurt TB treatment.

Interruptions in drug supplies have hindered treatment of multidrug-resistant and extensively drug-resistant tuberculosis in the U.S. in recent years, according to a recent study.

Published in the Jan. 17 Morbidity and Mortality Weekly Report, the study found that 81 percent of the 26 health departments reporting multidrug-resistant TB in 2005-2010 faced difficulties procuring second-line drugs. The health departments cited nation-wide shortages, shipping delays, lack of resources and a complicated procurement process related to investigational new drug protocols as the main reasons for the difficulty.

Trouble procuring the medication sometimes resulted in treatment delay, a treatment lapse or interruption, or the use of an inadequate regimen, according to the study. Potential solutions for alleviating medication shortages include stockpiling drugs, sharing drugs among jurisdictions, obtaining drugs from foreign manufacturers and "taking advantage of new legal requirements for drug suppliers to report shortages and impending shortages to FDA within a specific timeframe," the study's authors wrote.
COPYRIGHT 2013 The Nation's Health
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:NATION IN BRIEF.
Author:Currie, Donya
Publication:The Nation's Health
Date:Mar 1, 2013
Previous Article:New flu vaccine based on insects, not eggs.
Next Article:Q&A with NIEHS Director Linda Birnbaum: looking toward the future of new environmental research.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters